Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary?

Up to 40% of total weight loss from antiobesity medications may come from fat-free mass.

• Weight loss from glucagon-like peptide-1 receptor analogs (GLP-1 RA) can significantly reduce fat-free mass (FFM), which includes nonmuscle components.
• Skeletal muscle mass (SM) specifically is a concern during weight loss, as loss of muscle can lead to sarcopenia.
• Resistance training and adequate protein intake may help reduce muscle loss, but evidence regarding their effectiveness alongside GLP-1 RA therapy is mixed.
• Certain nutrients, such as branched chain amino acids, creatine, leucine, omega-3 fatty acids, and vitamin D, could aid in preserving muscle mass.
• Emerging treatments like bimagrumab and other activin or myostatin inhibitors may offer new options for maintaining muscle mass while promoting fat loss.

AI simplified